Study S002736

Investigation on Safety, Tolerability, and Pharmacokinetics of Single Doses of a Long-acting GLP-1 Analogue in Healthy Male Subjects

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT01405261
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1
Masking: DOUBLE
Status: COMPLETED
Enrollment: 101
Start: 2011-08
Primary completion: 2012-05
Lead sponsor: Novo Nordisk A/S
Conditions: Diabetes; Diabetes Mellitus, Type 2; Healthy
Interventions: DRUG:oral NNC 0113-0987; DRUG:I.v. NNC 0113-0987; DRUG:oral placebo
Results posted: FALSE
Secondary identifiers: OTHER:U1111-1119-1560; EUDRACT_NUMBER:2011-000297-57

Registered primary outcomes

Overview of Treatment Emergent Adverse Events (AEs) [Up to 25 days after trial product administration]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.